- Home
- ROIV vs DRS Comparison
ROIV vs DRS Comparison
Compare ROIV & DRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- DRS
- Stock Information
- Founded
- ROIV 2014
- DRS 1969
- Country
- ROIV United Kingdom
- DRS United States
- Employees
- ROIV N/A
- DRS N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- DRS Military/Government/Technical
- Sector
- ROIV Health Care
- DRS Industrials
- Exchange
- ROIV Nasdaq
- DRS Nasdaq
- Market Cap
- ROIV 8.4B
- DRS 8.3B
- IPO Year
- ROIV N/A
- DRS N/A
- Fundamental
- Price
- ROIV $10.79
- DRS $41.67
- Analyst Decision
- ROIV Buy
- DRS Buy
- Analyst Count
- ROIV 4
- DRS 6
- Target Price
- ROIV $17.50
- DRS $38.33
- AVG Volume (30 Days)
- ROIV 5.9M
- DRS 1.1M
- Earning Date
- ROIV 05-29-2025
- DRS 05-01-2025
- Dividend Yield
- ROIV N/A
- DRS 0.43%
- EPS Growth
- ROIV N/A
- DRS 25.90
- EPS
- ROIV N/A
- DRS 0.88
- Revenue
- ROIV $122,585,000.00
- DRS $3,345,000,000.00
- Revenue This Year
- ROIV N/A
- DRS $9.55
- Revenue Next Year
- ROIV N/A
- DRS $6.15
- P/E Ratio
- ROIV N/A
- DRS $47.35
- Revenue Growth
- ROIV 140.04
- DRS 13.58
- 52 Week Low
- ROIV $8.73
- DRS $21.98
- 52 Week High
- ROIV $13.06
- DRS $42.62
- Technical
- Relative Strength Index (RSI)
- ROIV 50.06
- DRS 67.49
- Support Level
- ROIV $10.58
- DRS $40.01
- Resistance Level
- ROIV $11.77
- DRS $43.20
- Average True Range (ATR)
- ROIV 0.34
- DRS 1.59
- MACD
- ROIV -0.07
- DRS -0.07
- Stochastic Oscillator
- ROIV 17.65
- DRS 79.35
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About DRS Leonardo DRS Inc.
Leonardo DRS Inc is a provider of defense products and technologies that are used across land, air, sea, space, and cyber domains. The company is in the design, development, and manufacture of Advanced sensing, network computing, force protection, and electric power and propulsion technologies and solutions. The company has two segments: Advanced Sensing and Computing, which generates the majority of revenue, and the Integrated Mission Systems segment. The Advanced Sensing and Computing segment is engaged in designing, developing, and manufacturing sensing and network computing technology that enables real-time situational awareness required for enhanced operational decision-making and execution by the customers.